Hyphens Pharma seeks listing as it hunts for potential business partners, acquisitions

Benjamin Cher
Benjamin Cher5/21/2018 08:00 AM GMT+08  • 6 min read
Hyphens Pharma seeks listing as it hunts for potential business partners, acquisitions
SINGAPORE (May 21): The healthcare universe on Singapore Exchange will see the entry of another stock, Hyphens Pharma International.  
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (May 21): The healthcare universe on Singapore Exchange will see the entry of another stock, Hyphens Pharma International.

The company has launched its IPO on Catalist. It is selling 29.6 million shares at 26 cents each. Three million shares were made available to the public. These have been 152 times oversubscribed. The rest of the shares are being privately placed out, with 2.8 million shares reserved for directors and employees of Hyphens Pharma. Separately, three cornerstone investors — Nikko Asset Management Asia, Qilin Asset Management and Maxi-Harvest Group — will subscribe to 30.4 million cornerstone shares. The market capitalisation of Hyphens Pharma after its IPO will be about $78 million, or 13 times its earnings last year.

Hyphens Pharma is seeking to raise $15.6 million, of which $7 million will be earmarked for business expansion, including potential acquisitions, product development and research.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.